Peptide Science Oregon

Peptide Science Oregon: A Thriving Frontier of Research, Therapeutics, and Regulatory Change

In 2026, Peptide Science Oregon stands at the center of a rapidly evolving peptide landscape. The state has emerged as a notable hub where groundbreaking academic research, a growing clinical therapeutics sector, and one of the most dramatic corporate events in modern peptide history intersect. Understanding the full scope of Peptide Science Oregon means looking simultaneously at three interconnected layers: the world-class research at its universities, the expanding clinical ecosystem, and the commercial forces that have reshaped the entire industry.

The Rise and Fall of Peptide Science Oregon: A $7.4 Million Per Month Operation

Perhaps the most headline-grabbing development in Oregon’s peptide sector was the rise and sudden shutdown of Peptide Sciences. At its peak, the company—widely regarded as the largest gray market peptide vendor in the United States—was generating an estimated $7.4 million in monthly revenue. For years, the company was a dominant force in the research peptide market, supplying high-purity peptides and research chemicals to scientists, biohackers, and wellness enthusiasts nationwide.

But on March 6, 2026, Peptide Sciences went dark. Its website was replaced with a brief message announcing the voluntary cessation of operations. The shutdown was not precipitated by a raid, as many initially assumed, but was instead a calculated decision. As one industry observer put it, the company “made a quarter billion and walked away at the top,” choosing to exit rather than fight an escalating FDA enforcement apparatus for years to come.

The regulatory environment had been tightening steadily. In October 2023, the FDA designated a range of popular peptides as Category 2 compounds, effectively banning them from licensed pharmacy compounding. Then, in June 2025, federal agents raided Amino Asylum’s warehouse, marking a dramatic escalation from warning letters to physical seizures. By September 2025, more than 50 warning letters had been issued to GLP-1 vendors. And in December 2025, criminal guilty pleas were entered by Paradigm Peptides founders and Tailor Made Compounding, demonstrating that the Department of Justice would pursue criminal prosecution.

Peptide Sciences’ closure sent shockwaves through the industry. Researchers scrambled to rebuild their supplier shortlists, and patients accustomed to the company’s products faced sudden uncertainty. As Andrew Huberman, the Stanford neuroscientist, noted: “The FDA isn’t killing peptides. They’re killing the gray market distribution channel.” The molecules themselves remain, but the unregulated vendors that once dominated their supply are rapidly disappearing.

The Academic Powerhouses: Where Oregon’s Real Peptide Innovation Lives

While the commercial turmoil has captured headlines, the deeper story of peptide science in Oregon lies in its world-class research institutions. The state is home to an impressive array of university-based peptide research that is quietly pushing the boundaries of medicine and biotechnology.

Oregon State University: Defeating Antibiotic Resistance with Antimicrobial Peptides

At Oregon State University, the Cotten group, led by Associate Professor Myriam Cotten, is conducting pioneering research on antimicrobial peptides as potential weapons against drug-resistant bacteria. The threat is immense: in 2021, nearly five million people died from antimicrobial resistance, and projections suggest almost 40 million deaths between 2025 and 2050.

Cotten’s research focuses on understanding why certain antimicrobial peptides are more effective at disrupting bacterial membranes. By combining lab experiments with computational modeling, her team developed a mathematical equation that relates the effectiveness of membrane damage to pore characteristics—specifically, that more effective peptides form larger and more numerous pores that remain open longer. This work provides a rational framework for designing novel antimicrobial compounds to fight infections that no longer respond to conventional antibiotics. Current projects in the Cotten group also include multi-hit host defense peptides and cell-penetrating peptides, studied using advanced solid-state NMR spectroscopy.

University of Oregon: Computational Design of Permeable Peptide Therapeutics

At the University of Oregon’s Phil and Penny Knight Campus for Accelerating Scientific Impact, Assistant Professor Parisa Hosseinzadeh has earned a $2.1 million NIH Director’s New Innovator Award to tackle one of peptide therapeutics’ most persistent challenges: cellular permeability.

Hosseinzadeh’s approach is distinctly modern. She uses computer modeling and machine learning to design synthetic peptides that can both bind strongly to protein targets like antibodies and cross cell membranes to access intracellular targets like small molecules. Her project, “A data-driven approach towards generation of permeable peptide therapeutics,” combines state-of-the-art computational techniques with experimental validation to develop methods and datasets that will serve as resources for the broader drug discovery community.

The therapeutic potential is enormous: these engineered peptides could address diseases ranging from cancer to emerging pandemics, filling a gap between conventional small molecules and monoclonal antibodies.

OHSU: Enabling Infrastructure for Peptide Research

Oregon Health & Science University provides critical infrastructure through its Medicinal Chemistry Core. The core performs custom solid-phase peptide synthesis (SPPS) for modified peptides, handling modifications including fluorophores, unnatural amino acids, cyclization, and terminal modifications.

Equipped with state-of-the-art instrumentation including a CEM Liberty Blue automated solid-phase peptide synthesizer, the core serves researchers across the OHSU community, with a team possessing more than fifty years of combined experience in medicinal chemistry and chemical biology. This centralized resource dramatically lowers the barrier for OHSU investigators to incorporate custom-designed peptides into their research programs.

From Bench to Bedside: Oregon’s Clinical Peptide Ecosystem

Beyond academia, Oregon has developed a vibrant clinical peptide therapy sector. Clinics in Portland, Bend, Tualatin, and elsewhere now offer medically supervised peptide programs for patients seeking support for recovery, metabolism, healthy aging, and overall wellness.

Flow Wellness in Bend, for example, provides personalized peptide therapy using only licensed 503(a) compounding pharmacies—explicitly rejecting the unregulated research-grade products that defined the gray market. Their offerings include Sermorelin and Tesamorelin for growth hormone support, alongside comprehensive medical evaluation and monthly clinician check-ins.

Meanwhile, clinics integrating the EvexiPEL Method report using peptide therapy to enhance hormone receptor sensitivity, support adrenal function, improve metabolic health, and accelerate tissue repair. The clinical consensus, as articulated by these practitioners, is that peptides are signaling molecules that work with the body’s own physiology rather than overriding it—offering cumulative, restorative benefits rather than immediate, pharmacological shortcuts.

Even as the gray market contracts, Oregon physicians emphasize that a meaningful portfolio of peptides remains available through legitimate channels: Sermorelin, PT-141 (bremelanotide), NAD+, GHK-Cu, and the GLP-1 agonists semaglutide and tirzepatide can all be obtained via prescription from licensed compounding pharmacies, with proper medical oversight.

Commercialization and Startups: The Business of Peptides in Oregon

Oregon is not merely a site of research and clinical application—it is also home to a growing cluster of peptide-focused companies, each occupying a distinct niche in the commercial ecosystem.

Synthetech, based in Albany, Oregon, represents the industrial backbone of the sector. The company specializes in organic synthesis, biocatalysis, and chiral technologies, manufacturing amino acid derivatives, peptide fragments, and proprietary chiral intermediates for the pharmaceutical industry. It operates under current Good Manufacturing Practices (cGMP) and in full compliance with FDA regulations.

13therapeutics, a spin-out from OHSU founded in 2008 in Portland, has built a portfolio of peptide therapeutics with immune-regulatory activity. The company has exclusively licensed its peptides on a worldwide basis and holds U.S. patents covering composition and use in all inflammatory conditions involving Toll-Like Receptor signaling. Their peptides, derived from naturally occurring pathogens, are designed to modulate the human immune response for treating acute and chronic inflammatory diseases such as rheumatoid arthritis, meningitis, and traumatic brain injury. Though small—just four employees—the company serves as a model of how academic discoveries in Oregon can be translated into commercial therapeutics.

Rogue Valley Peptides LLC, registered in Central Point, illustrates the presence of smaller, more localized players in the state. The Oregon Startup Center and the OTRADI Bioscience Incubator provide the infrastructure for bioscience commercialization, offering mentoring, office space, and networking to nurture the next generation of peptide-focused ventures.

The Path Forward: What the Oregon Experience Teaches Us

The story of peptide science in Oregon offers a remarkably complete picture of where the field stands today. We see the full arc: foundational research at OSU, UO, and OHSU; translation into therapeutic candidates through startups like 13therapeutics; infrastructure for synthesis and supply via cores and manufacturers like Synthetech; clinical application at wellness clinics across the state; and the cautionary tale of Peptide Sciences, reminding us that innovation without regulatory alignment carries existential risk.

The FDA has not killed peptides. But it has made clear that the era of the unregulated gray market is ending. The path forward for peptide science—in Oregon and beyond—lies in rigorous academic research, legitimate clinical application under proper oversight, and commercial models built on regulatory compliance rather than avoidance. Oregon, with its remarkable concentration of all three, is poised to lead the way.